Fresenius Medical Care Renal Therapies Group Announces Four Abstracts on Velphoro® Accepted for Presentation at the American...
November 03 2017 - 10:56AM
Business Wire
Data Demonstrates Switching Patients to
Velphoro Doubled the Percentage of Patients Achieving Serum
Phosphorus Control
Fresenius Medical Care Renal Therapies Group announced today
that four abstracts on Velphoro® (sucroferric oxyhydroxide) have
been accepted for presentation at the American Society of
Nephrology (ASN) annual Kidney Week held Oct. 31-Nov. 5, 2017 in
New Orleans.
The abstracts describe the real world outcomes in serum
phosphorus control and a significant reduction in pill burden
achieved in hemodialysis patients who switched to Velphoro as part
of their routine clinical care.
Two abstracts focus on a two-year follow-up of patients and
include sub-analyses based on the patients’ previous phosphate
binder therapy. One abstract documents the changes in mineral bone
disease markers in hyperphosphatemic patients who achieved target
phosphorus ranges. The fourth abstract describes the change in
nutritional markers among patients with low serum albumin who
switched to Velphoro.
“Real world data demonstrates switching patients to Velphoro
doubled the percentage of patients achieving serum phosphorus
control. DOPPS Practice Monitor highlights up to 35 percent of
patients are outside of their target phosphorus goal at any given
time,” explained Mark Costanzo, president, Fresenius Medical Care
Renal Therapies Group.
All four abstracts were accepted for poster presentations on
Thursday, Nov. 2. All four are available online on the conference’s
website:
https://www.asn-online.org/education/kidneyweek/2017/program-search-abstract.aspx.
Poster Presentations
1) “Effectiveness of Sucroferric Oxyhydroxide (SO) in
Lowering Serum Phosphorus (sP) in 4,925 Chronic Hemodialysis (HD)
Patients Prescribed SO as part of routine care." Daniel W.
Coyne, Linda H. Ficociello, Vidhya Parameswaran, Norma J. Ofsthun,
Claudy Mullon, Robert J. Kossmann, Stuart M. Sprague Session
Title: 1201-PO01 Mineral Disease: Ca/Mg/PO4 Poster Board #:
TH-PO1031 2) “Two Year Follow Up on Chronic Hemodialysis
(HD) Patients Prescribed Sucroferric Oxyhydroxide as Part of
Routine Care" Stuart M. Sprague, Vidhya Parameswaran, Linda
H. Ficociello, Norma J. Ofsthun, Claudy Mullon, Robert J. Kossmann,
Daniel W. Coyne Session Title: 1201-PO01 Mineral Disease:
Ca/Mg/PO4 Poster Board #: TH-PO1030 3) “Serum Albumin
and Serum Phosphorus among Hemodialysis Patients after Initiating
Sucroferric Oxyhydroxide (SO)" Kamyar Kalantar-Zadeh, Linda
H. Ficociello, Vidhya Parameswaran, Hasi Mondal, Nicolaos V.
Athienites, Claudy Mullon, Robert J. Kossmann Session Title:
1201-PO01 Mineral Disease: Ca/Mg/PO4 Poster Board #:
TH-PO1033 4) “Changes in Mineral Bone Disease (MBD) Markers
in Hemodialysis (HD) Patients Switched to Sucroferric Oxyhydroxide
(SO)." Sandeep Shori, Vidhya Parameswaran, Linda H.
Ficociello, Claudy Mullon, Robert J. Kossmann Session Title:
1201-PO01 Mineral Disease: Ca/Mg/PO4 Poster Board #:
TH-PO1032
INDICATION
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder
indicated for the control of serum phosphorus levels in patients
with chronic kidney disease on dialysis.
IMPORTANT SAFETY INFORMATION
- Velphoro must be administered with
meals. Velphoro tablets must be chewed and not swallowed whole. To
aid with chewing and swallowing, the tablets may be crushed.
- Patients with peritonitis during
peritoneal dialysis, significant gastric or hepatic disorders,
following major gastrointestinal (GI) surgery, or with a history of
hemochromatosis or other disease with iron accumulation have not
been included in clinical studies with Velphoro. Monitor effect and
iron homeostasis in such patients.
- In a parallel design, fixed-dose study
of six weeks duration, the most common adverse drug reactions to
Velphoro chewable tablets in hemodialysis patients included
discolored feces (12%) and diarrhea (6%).
- Velphoro can be administered
concomitantly with oral calcitriol, ciprofloxacin, digoxin,
enalapril, furosemide, HMG-CoA reductase inhibitors,
hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole,
quinidine and warfarin. Take doxycycline at least one hour before
Velphoro. Velphoro should not be prescribed with oral
levothyroxine.
For more information, please see full Prescribing Information,
contact your Fresenius Medical Care North America representative or
visit www.Velphoro.us/hcp.
About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier health care
company focused on providing the highest quality care to people
with renal and other chronic conditions. Through its
industry-leading network of dialysis facilities, outpatient cardiac
and vascular labs, and urgent care centers, as well as the
country’s largest practice of hospitalist and post-acute providers,
Fresenius Medical Care North America provides coordinated health
care services at pivotal care points for hundreds of thousands of
chronically ill customers throughout the continent. As the world’s
largest fully integrated renal company, it offers specialty
pharmacy and laboratory services, and manufactures and distributes
the most comprehensive line of dialysis equipment, disposable
products and renal pharmaceuticals. For more information, visit the
FMCNA website at https://fmcna.com.
*Source: https://www.dopps.org/dpm/, accessed 10/30/2017
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171103005570/en/
For More Information:Charles DeLoachFresenius Medical
Care Renal Therapies GroupSenior Vice President of Sales and
Marketingcharles.deloach@fmc-na.com(781) 699-4310orMedia
Contact:Kate DobbsFresenius Medical Care North AmericaVice
President of Corporate
Communicationskatherine.dobbs@fmc-na.com(781) 699-9039
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fresenius Medical Care (NYSE:FMS)
Historical Stock Chart
From Apr 2023 to Apr 2024